Trial Profile
To compare healthcare costs and resource utilization for overactive bladder patients who persisted on Mirabegron with those who switched to Onabotulinumtoxina
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Nov 2017
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 29 Nov 2017 New trial record